{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.234","upperLimit":"0.324","value":"0.277"},{"groupId":"OG001","lowerLimit":"0.132","upperLimit":"0.209","value":"0.168"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"397"},{"groupId":"OG001","value":"393"}],"units":"Participants"}],"description":"PSA CR is defined as a PSA level less than 0.2 ng/ml measured for 2 consecutive measurements at least 4 weeks apart. Patients who met the criterion of PSA CR and had PSA level less than 0.2 ng/ml before and after the 12-month time point are considered as having a PSA CR at 12 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \\[LHRH\\] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Androgen-Deprivation Therapy and Docetaxel"},{"description":"Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone \\[LHRH\\] agonist therapy, LHRH antagonist therapy, or surgical castration).","id":"OG001","title":"Androgen-Deprivation Therapy Alone"}],"paramType":"NUMBER","populationDescription":"All randomized patients","reportingStatus":"POSTED","timeFrame":"Assessed at 12 months","title":"Proportion of Patients With PSA Complete Response (CR) at 12 Months","type":"SECONDARY","unitOfMeasure":"proportion of participants"}